Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

Invivyd, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW HAVEN, CONN., OCT. 06, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (NASDAQ: IVVD) TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS CLEARED THE COMPANY'S INVESTIGATIONAL NEW DRUG (IND) APPLICATION AND PROVIDED FEEDBACK TO ADVANCE THE COMPANY'S REVOLUTION CLINICAL PROGRAM, INVIVYD'S DEVELOPMENT PROGRAM FOR VYD2311, A VACCINE ALTERNATIVE MONOCLONAL ANTIBODY CANDIDATE FOR THE PREVENTION OF COVID.

INVIVYD ANNOUNCES U.S. IND CLEARANCE AND ALIGNMENT WITH U.S. FDA ON PIVOTAL CLINICAL PROGRAM FOR VYD2311, A VACCINE-ALTERNATIVE ANTIBODY TO PREVENT COVID

NEW HAVEN, CONN., SEPT. 24, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (NASDAQ: IVVD) TODAY ANNOUNCED THE APPOINTMENT OF PAUL B. BOLNO, M.D., TO ITS BOARD OF DIRECTORS AND AS A MEMBER OF THE COMPENSATION COMMITTEE. DR. BOLNO IS THE PRESIDENT AND CEO OF WAVE LIFE SCIENCES, A CLINICAL-STAGE BIOTECHNOLOGY COMPANY, AND HAS SERVED IN THOSE ROLES SINCE 2013.

INVIVYD APPOINTS PAUL B. BOLNO, M.D.

NEW HAVEN, CONN., SEPT. 17, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (NASDAQ: IVVD) TODAY ANNOUNCED THE APPOINTMENT OF KRISTIE KUHL AS CHIEF COMMUNICATIONS OFFICER. MS. KUHL WILL LEAD THE COMPANY'S COMMUNICATIONS AND PATIENT ADVOCACY EFFORTS AS INVIVYD ADVANCES ITS MISSION OF PROVIDING MONOCLONAL ANTIBODIES FOR THE PREVENTION AND TREATMENT OF VIRAL DISEASE.

INVIVYD ANNOUNCES APPOINTMENT OF KRISTIE KUHL AS CHIEF COMMUNICATIONS OFFICER

WALTHAM, MASS., SEPT. 04, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (NASDAQ: IVVD) TODAY ANNOUNCED THAT THE SPEAR STUDY GROUP HAS ISSUED THEIR CONSENSUS RECOMMENDATION FOR A CLINICAL STUDY DESIGN TO EVALUATE THE EFFECTS OF MONOCLONAL ANTIBODY (MAB) THERAPY ON LONG COVID. THE RECOMMENDATION WILL BE PRESENTED FOR CONSIDERATION TO RECOVER-TLC, AN NIH INITIATIVE DEVOTED TO TESTING POTENTIAL TREATMENTS FOR LONG COVID.

SPEAR STUDY GROUP TO PRESENT ITS RECOMMENDED LONG COVID ANTIBODY STUDY DESIGN FEATURING INVIVYD'S VYD2311 AT RECOVER-TLC WORKSHOP SEPTEMBER 9-10, 2025

WALTHAM, MASS., AUG. 27, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (NASDAQ: IVVD) TODAY ANNOUNCED THAT IT WILL PRESENT AT THE FOLLOWING INVESTOR CONFERENCES: CANTOR GLOBAL HEALTHCARE CONFERENCE 2025 FIRESIDE CHAT DATE: WEDNESDAY, SEPTEMBER 3, 2025FIRESIDE CHAT TIME: 2:10 PM ETLOCATION: NEW YORK, NY H.C.

INVIVYD TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

WALTHAM, MASS., AUG. 22, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (INVIVYD) (NASDAQ: IVVD) TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 89,234,480 SHARES OF ITS COMMON STOCK, WHICH INCLUDES THE EXERCISE IN FULL BY THE UNDERWRITER OF ITS OPTION TO PURCHASE AN ADDITIONAL 14,423,076 SHARES OF COMMON STOCK, AT A PUBLIC OFFERING PRICE OF $0.52 PER SHARE AND PRE-FUNDED WARRANTS TO PURCHASE 21,342,442 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $0.5199 PER PRE-FUNDED WARRANT, WHICH REPRESENTS THE PER SHARE PRICE FOR THE COMMON STOCK LESS THE $0.0001 PER SHARE EXERCISE PRICE FOR EACH SUCH PRE-FUNDED WARRANT. ALL OF THE SHARES AND PRE-FUNDED WARRANTS WERE OFFERED BY INVIVYD. THE GROSS PROCEEDS FROM THIS OFFERING WERE APPROXIMATELY $57.5 MILLION, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OFFERING EXPENSES PAYABLE BY INVIVYD.

INVIVYD ANNOUNCES CLOSING OF $57.5 MILLION PUBLIC OFFERING AND FULL EXERCISE OF THE UNDERWRITER'S OPTION TO PURCHASE ADDITIONAL SHARES

WALTHAM, MASS., AUG. 20, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (INVIVYD) (NASDAQ: IVVD) TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 74,811,404 SHARES OF ITS COMMON STOCK AT AN OFFERING PRICE OF $0.52 PER SHARE AND, TO CERTAIN INVESTORS, IN LIEU OF COMMON STOCK, PRE-FUNDED WARRANTS TO PURCHASE 21,342,442 SHARES OF ITS COMMON STOCK AT A PRICE OF $0.5199 PER PRE-FUNDED WARRANT.

INVIVYD ANNOUNCES PRICING OF $50 MILLION PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

WALTHAM, MASS., AUG. 20, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (INVIVYD) (NASDAQ: IVVD) TODAY ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF SHARES OF ITS COMMON STOCK. IN ADDITION, INVIVYD INTENDS TO GRANT THE UNDERWRITERS AN OPTION FOR A PERIOD OF 30 DAYS TO PURCHASE UP TO AN ADDITIONAL 15% OF THE SHARES OF INVIVYD COMMON STOCK SOLD IN THE PUBLIC OFFERING AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. ALL OF THE SHARES ARE BEING OFFERED BY INVIVYD. THE OFFERING IS SUBJECT TO MARKET AND OTHER CONDITIONS AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED, OR AS TO THE ACTUAL SIZE OR TERMS OF THE OFFERING.

INVIVYD ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

WALTHAM, MASS., AUG. 18, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (NASDAQ: IVVD) TODAY ANNOUNCED POSITIVE, CONTINUED, CLINICALLY MEANINGFUL IN VITRO NEUTRALIZATION DATA FOR PEMGARDA (PEMIVIBART) AGAINST THE CURRENTLY DOMINANT AND GROWING XFG VARIANT OF SARS-COV-2. NOTABLY, AND CONSISTENT WITH ALL DOMINANT VARIANTS FOR THE PAST THREE YEARS, XFG DID NOT GENERATE ANY MEANINGFUL CHANGE TO THE IN VITRO NEUTRALIZATION ACTIVITY OF PEMIVIBART OR VYD2311, THE COMPANY'S NEXT GENERATION COVID-19 MONOCLONAL ANTIBODY (MAB) CANDIDATE, AS THE EPITOPES TARGETED BY PEMIVIBART AND VYD2311 REMAIN STRUCTURALLY INTACT. PEMGARDA (PEMIVIBART) IS AUTHORIZED BY THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR PRE-EXPOSURE PROPHYLAXIS OF COVID-19 IN CERTAIN IMMUNOCOMPROMISED PATIENTS.

INVIVYD ANNOUNCES CONTINUED NEUTRALIZING ACTIVITY OF PEMGARDA (PEMIVIBART) AND VYD2311 AGAINST CURRENTLY DOMINANT SARS-COV-2 VARIANT XFG (STRATUS)

WALTHAM, MASS., AUG. 14, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (NASDAQ: IVVD) TODAY ANNOUNCED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025, AND PROVIDED RECENT BUSINESS HIGHLIGHTS.

INVIVYD REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

ALIGNMENT FOLLOWS TYPE C MEETING FOR VYD2311 AS PREVIOUSLY DISCLOSED BLA PATHWAY FOR VYD2311 TO BE SUPPORTED BY A SINGLE, PHASE 2/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL WITH A PRIMARY ENDPOINT OF REDUCTION IN SYMPTOMATIC COVID-19, RESEMBLING CANOPY COHORT B COMPANY'S TARGET PRODUCT PROFILE IS LOW-DOSE, INTRAMUSCULAR, SCALABLE, LOW-COST, LONG-LASTING, PROTECTIVE OPTION FOR TARGET POPULATIONS, INCLUDING ADULTS AND ADOLESCENTS (12 YEARS+; 40KG+) AND, SUBJECT TO FDA ALIGNMENT, PEDIATRICS (AGED 0 TO 12 YEARS) ANTICIPATE COMPACT TRIAL (12-WEEK PRIMARY ENDPOINT ANALYSIS) EVALUATING PREVENTION OF COVID-19 LARGELY AMONG ORDINARY AMERICANS, ENABLING RAPID ENROLLMENT PLANNED HEAD-TO-HEAD SAFETY EVALUATION WITH COVID-19 VACCINE, PENDING REGULATORY ALIGNMENT QUANTITIES OF VYD2311 POTENTIAL COMMERCIAL LAUNCH PRODUCT AVAILABLE WALTHAM, MASS., AUG. 14, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (NASDAQ: IVVD) TODAY ANNOUNCED IT HAS RECEIVED AND IS ALIGNED WITH ADVICE FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) ON A COMPACT AND, THEREFORE, RAPID PATHWAY TO POTENTIAL BIOLOGICS LICENSE APPLICATION (BLA) APPROVAL FOR INVIVYD'S NOVEL MONOCLONAL ANTIBODY (MAB) CANDIDATE VYD2311, FOR THE PREVENTION OF COVID-19.

INVIVYD ALIGNS WITH U.S. FDA ON RAPID PATHWAY TO FULL APPROVAL (BLA) OF VACCINE ALTERNATIVE MONOCLONAL ANTIBODY VYD2311 TO PROTECT AMERICAN ADULTS AND ADOLESCENTS FROM COVID-19

Invivyd, Inc.

IVVD

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Invivyd, Inc.

IVVD.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

IVVD